An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody
IMPORTANCE: The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
mBio - 15(2024), 1 vom: 16. Jan., Seite e0247723 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Atanasoff, Kristina E [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 17.01.2024 Date Revised 18.02.2024 published: Print-Electronic UpdateOf: bioRxiv. 2023 Apr 21;:. - PMID 37131698 Citation Status MEDLINE |
|---|
| doi: |
10.1128/mbio.02477-23 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365456489 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365456489 | ||
| 003 | DE-627 | ||
| 005 | 20240218231911.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/mbio.02477-23 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1298.xml |
| 035 | |a (DE-627)NLM365456489 | ||
| 035 | |a (NLM)38054729 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Atanasoff, Kristina E |e verfasserin |4 aut | |
| 245 | 1 | 3 | |a An in vitro experimental pipeline to characterize the epitope of a SARS-CoV-2 neutralizing antibody |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.01.2024 | ||
| 500 | |a Date Revised 18.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: bioRxiv. 2023 Apr 21;:. - PMID 37131698 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a IMPORTANCE: The COVID-19 pandemic remains a significant public health concern for the global population; the development and characterization of therapeutics, especially ones that are broadly effective, will continue to be essential as severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) variants emerge. Neutralizing monoclonal antibodies remain an effective therapeutic strategy to prevent virus infection and spread so long as they recognize and interact with circulating variants. The epitope and binding specificity of a neutralizing anti-SARS-CoV-2 Spike receptor-binding domain antibody clone against many SARS-CoV-2 variants of concern were characterized by generating antibody-resistant virions coupled with cryo-EM structural analysis and VSV-spike neutralization studies. This workflow can serve to predict the efficacy of antibody therapeutics against emerging variants and inform the design of therapeutics and vaccines | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a cryo-EM | |
| 650 | 4 | |a epitope mapping | |
| 650 | 4 | |a neutralizing antibody | |
| 650 | 4 | |a structural analysis | |
| 650 | 4 | |a viral resistance | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Brambilla, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Adelsberg, Daniel C |e verfasserin |4 aut | |
| 700 | 1 | |a Kowdle, Shreyas |e verfasserin |4 aut | |
| 700 | 1 | |a Stevens, Christian S |e verfasserin |4 aut | |
| 700 | 1 | |a Slamanig, Stefan |e verfasserin |4 aut | |
| 700 | 1 | |a Hung, Chuan-Tien |e verfasserin |4 aut | |
| 700 | 1 | |a Fu, Yanwen |e verfasserin |4 aut | |
| 700 | 1 | |a Lim, Reyna |e verfasserin |4 aut | |
| 700 | 1 | |a Tran, Linh |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Weina |e verfasserin |4 aut | |
| 700 | 1 | |a Duty, J Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Bajic, Goran |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Benhur |e verfasserin |4 aut | |
| 700 | 1 | |a Tortorella, Domenico |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mBio |d 2010 |g 15(2024), 1 vom: 16. Jan., Seite e0247723 |w (DE-627)NLM200128191 |x 2150-7511 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2024 |g number:1 |g day:16 |g month:01 |g pages:e0247723 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/mbio.02477-23 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2024 |e 1 |b 16 |c 01 |h e0247723 | ||